Oncotarget

Research Papers:

Development and validation of nomogram based on lncRNA ZFAS1 for predicting survival in lymph node-negative esophageal squamous cell carcinoma patients

Hongtai Shi, Zhenhua Liu, Dong Pei, Youqin Jiang, Haiwen Zhu and Bin Chen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:59048-59057. https://doi.org/10.18632/oncotarget.19937

Metrics: PDF 1039 views  |   HTML 1448 views  |   ?  


Abstract

Hongtai Shi1,*, Zhenhua Liu2,*, Dong Pei1,*, Youqin Jiang1, Haiwen Zhu1 and Bin Chen1

1Department of Radiotherapy, The Third People’s Hospital of Yancheng, Yancheng 224005, China

2Department of Radiotherapy, Yancheng City No.1 People’s Hospital, Yancheng 224000, China

*These authors contributed equally to this work

Correspondence to:

Bin Chen, email: 15189200911@163.com

Keywords: lncRNA, ZFAS1, nomogram, ESCC

Received: July 05, 2017     Accepted: July 26, 2017     Published: August 04, 2017

ABSTRACT

Background: There is increasing evidence of a relationship between long non-coding RNA (lncRNA) and cancer. This study aimed to examine the prognostic value of the lncRNA ZFAS1 in esophageal squamous cell carcinoma (ESCC).

Results: The results showed that ZFAS1 expression was significantly higher in ESCC tissues compared with the corresponding adjacent normal tissues (P < 0.001). ESCC patients with high ZFAS1 expression had a poor overall survival (OS). Histological grade, T stage and ZFAS1 expression were integrated to develop the nomogram. The nomogram showed a significantly better prediction of OS for patients with lymph node-negative ESCC. The ROC curve also showed higher specificity and sensitivity for predicting 3- and 5-year ESCC patient survival compared with the AJCC staging system. The decision curve analysis also indicated a greater potential for the nomogram in clinical application compared with the AJCC staging system. Importantly, our findings were supported by a validation cohort.

Materials and Methods: We retrospectively investigated 398 lymph node-negative ESCC patients. Data from the primary cohort (n = 246) were used to develop a multivariate nomogram. The nomogram was internally validated for discrimination and calibration with bootstrap samples and was externally validated with an independent patient cohort (n = 152).

Conclusions: Our proposed nomogram, which integrates clinicopathological factors and ZFAS1 expression, can accurately predict the prognosis of lymph node-negative ESCC patients without preoperative chemoradiotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19937